<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0120-8748</journal-id>
<journal-title><![CDATA[Acta Neurológica Colombiana]]></journal-title>
<abbrev-journal-title><![CDATA[Acta Neurol Colomb.]]></abbrev-journal-title>
<issn>0120-8748</issn>
<publisher>
<publisher-name><![CDATA[Asociación Colombiana de Neurología]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0120-87482019000200064</article-id>
<article-id pub-id-type="doi">10.22379/24224022236</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Síndrome clínico aislado: abordaje del primer evento desmielinizante]]></article-title>
<article-title xml:lang="en"><![CDATA[Clinically isolated syndrome: approach to the first demyelinating event]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Casallas Vanegas]]></surname>
<given-names><![CDATA[Adriana]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Zuluaga Rodas]]></surname>
<given-names><![CDATA[Maria Isabel]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Reyes Guerrero]]></surname>
<given-names><![CDATA[Marco Aurelio]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad de la Sabana  ]]></institution>
<addr-line><![CDATA[Bogotá ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad CES  ]]></institution>
<addr-line><![CDATA[Medellín ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Universidad Militar Nueva Granada  ]]></institution>
<addr-line><![CDATA[Bogotá ]]></addr-line>
<country>Colombia</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2019</year>
</pub-date>
<volume>35</volume>
<numero>2</numero>
<fpage>64</fpage>
<lpage>73</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_arttext&amp;pid=S0120-87482019000200064&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_abstract&amp;pid=S0120-87482019000200064&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_pdf&amp;pid=S0120-87482019000200064&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN El síndrome Clínico Aislado (SCA) denota al primer síntoma neurológico sugestivo de esclerosis múltiple (EM), de por lo menos 24 horas de duración; en ausencia de fiebre, procesos infecciosos y encefalopatía. Se caracteriza por su presentación frecuente en adultos jóvenes y afecta al nervio óptico, hemisferios cerebrales, tronco encefálico o médula espinal. La estratificación temprana del SCA es indispensable ya que con herramientas predictoras clínicas, radiológicas y biológicas, se puede establecer el riesgo de conversión a EM. El uso de terapias modificadoras de la enfermedad (TME) en el primer evento desmielinizante, ha demostrado retrasar la conversión de SCA a esclerosis múltiple en un 44 a 50 %. Sin embargo, no todos los pacientes con SCA evolucionarán a EM, por lo que el estudio de diversos marcadores prónosticos permitirá reconocer el escenario ideal donde los pacientes se beneficien del inicio temprano de TME.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[SUMMARY Clinically Isolated Syndrome (CIS), denotes the first neurological symptom suggestive of Multiple Sclerosis (MS), at least 24 hours in duration; In the absence of fever, infectious processes and encephalopathy. It is characterized by its frequent presentation in young adults and affects the optic nerve, brainstem or spinal cord. The early stratification of CIS is essential because with clinical, radiological and biological predictors, the risk of conversion to MS can be established. The use of Disease Modifying Therapies (DMT) in CIS has been shown to delay the conversion of CIS to Multiple Sclerosis by 44 to 50 %%. However, not all patients with CIS will evolve to MS, so the study of several prognostic markers will allow to recognize the ideal scenario where patients benefit from the early onset of DMT.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[enfermedad desmielinizante]]></kwd>
<kwd lng="es"><![CDATA[Bandas oligoclonales]]></kwd>
<kwd lng="es"><![CDATA[Esclerosis Múltiple]]></kwd>
<kwd lng="es"><![CDATA[Resonancia magnética]]></kwd>
<kwd lng="es"><![CDATA[Liquido cefalorraquideo]]></kwd>
<kwd lng="es"><![CDATA[tratamiento farmacológico (DeCS)]]></kwd>
<kwd lng="en"><![CDATA[Demyelinating Diseases]]></kwd>
<kwd lng="en"><![CDATA[Oligoclonal bands]]></kwd>
<kwd lng="en"><![CDATA[Multiple Sclerosis]]></kwd>
<kwd lng="en"><![CDATA[Magnetic Resonance]]></kwd>
<kwd lng="en"><![CDATA[Cerebroespinal Fluid]]></kwd>
<kwd lng="en"><![CDATA[Drug therapy (MeSH)]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Compston]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Coles]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Multiple sclerosis]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2008</year>
<volume>372</volume>
<page-range>1502-17</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Miller]]></surname>
<given-names><![CDATA[DH]]></given-names>
</name>
<name>
<surname><![CDATA[Chard]]></surname>
<given-names><![CDATA[DT]]></given-names>
</name>
<name>
<surname><![CDATA[Ciccarelli]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinically isolated syndromes]]></article-title>
<source><![CDATA[Lancet Neurol]]></source>
<year>2012</year>
<volume>11</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>157-69</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Miller]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Barkhof]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Montalban]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Thompson]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Filippi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinically isolated syndromes suggestive of multiple sclerosis, part I: Natural history, pathogenesis, diagnosis, and prognosis]]></article-title>
<source><![CDATA[Lancet Neurol]]></source>
<year>2005</year>
<volume>4</volume>
<page-range>281-8</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Confavreux]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Vukusic]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Adeleine]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Early clinical predictors and progression of irreversible disability in multiple sclerosis: An amnesic process]]></article-title>
<source><![CDATA[Brain]]></source>
<year>2003</year>
<volume>126</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>770-82</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Polman]]></surname>
<given-names><![CDATA[CH]]></given-names>
</name>
<name>
<surname><![CDATA[Reingold]]></surname>
<given-names><![CDATA[SC]]></given-names>
</name>
<name>
<surname><![CDATA[Banwell]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Clanet]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Cohen]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Filippi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria]]></article-title>
<source><![CDATA[Ann Neurol]]></source>
<year>2011</year>
<volume>69</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>292-302</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Compston]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Confavreux]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Lassmann]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[McDonald]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Miller]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Noseworthy]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Treatment of the acute relapse]]></article-title>
<source><![CDATA[McAlpine's multiple sclerosis]]></source>
<year>2006</year>
<page-range>683-99</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dalton]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[Bodini]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Samson]]></surname>
<given-names><![CDATA[RS]]></given-names>
</name>
<name>
<surname><![CDATA[Battaglini]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Fisniku]]></surname>
<given-names><![CDATA[LK]]></given-names>
</name>
<name>
<surname><![CDATA[Thompson]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Brain lesion location and clinical status 20 years after a diagnosis of clinically isolated syndrome suggestive of multiple sclerosis]]></article-title>
<source><![CDATA[Mult Scler]]></source>
<year>2012</year>
<volume>18</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>322-8</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Okuda]]></surname>
<given-names><![CDATA[DT]]></given-names>
</name>
<name>
<surname><![CDATA[Mowry]]></surname>
<given-names><![CDATA[EM]]></given-names>
</name>
<name>
<surname><![CDATA[Beheshtian]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Waubant]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Baranzini]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
<name>
<surname><![CDATA[Goodin]]></surname>
<given-names><![CDATA[DS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Incidental MRI anomalies suggestive of multiple sclerosis: The radiologically isolated syndrome]]></article-title>
<source><![CDATA[Neurology]]></source>
<year>2009</year>
<volume>72</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>800-5</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Keltner]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Johnson]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Spurr]]></surname>
<given-names><![CDATA[JO]]></given-names>
</name>
<name>
<surname><![CDATA[Beck]]></surname>
<given-names><![CDATA[RW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Baseline visual field profile of optic neuritis. The experience of the optic neuritis treatment trial. Optic Neuritis Study Group]]></article-title>
<source><![CDATA[Arch Ophthalmol]]></source>
<year>1993</year>
<volume>111</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>231-4</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hickman]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Dalton]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Miller]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Plant]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Management of acute optic neuritis]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2002</year>
<volume>360</volume>
<numero>9349</numero>
<issue>9349</issue>
<page-range>1953-62</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Toosy]]></surname>
<given-names><![CDATA[AT]]></given-names>
</name>
<name>
<surname><![CDATA[Mason]]></surname>
<given-names><![CDATA[DF]]></given-names>
</name>
<name>
<surname><![CDATA[Miller]]></surname>
<given-names><![CDATA[DH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Optic neuritis]]></article-title>
<source><![CDATA[Lancet Neurol]]></source>
<year>2014</year>
<volume>13</volume>
<page-range>83-99</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[de Seze]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Stojkovic]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Breteau]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Lucas]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Michon-Pasturel]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Gauvrit]]></surname>
<given-names><![CDATA[JY]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Acute myelopathies: Clinical, laboratory and outcome profiles in 79 cases]]></article-title>
<source><![CDATA[Brain]]></source>
<year>2001</year>
<volume>124</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1509-21</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Awad]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Hemmer]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Hartung]]></surname>
<given-names><![CDATA[HP]]></given-names>
</name>
<name>
<surname><![CDATA[Kieseier]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Bennett]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Stuve]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Analyses of cerebrospinal fluid in the diagnosis and monitoring of multiple sclerosis]]></article-title>
<source><![CDATA[J Neuroimmunol]]></source>
<year>2010</year>
<volume>219</volume>
<numero>1-2</numero>
<issue>1-2</issue>
<page-range>1-7</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cruccu]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Aminoff]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Curio]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Guerit]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Kakigi]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Mauguiere]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Recommendations for the clinical use of somatosensory-evoked potentials]]></article-title>
<source><![CDATA[Clin Neurophysiol]]></source>
<year>2008</year>
<volume>119</volume>
<page-range>1705-19</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rovira]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[León]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[MR in the diagnosis and monitoring of multiple sclerosis: An overview]]></article-title>
<source><![CDATA[Eur J Radiol]]></source>
<year>2008</year>
<volume>67</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>409-14</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tintoré]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Rovira]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Río]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Nos]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Grivé]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Téllez]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Baseline MRI predicts future attacks and disability in clinically isolated syndromes]]></article-title>
<source><![CDATA[Neurology]]></source>
<year>2006</year>
<volume>67</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>968-72</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<collab>Optic Neuritis Study Group TONS</collab>
<article-title xml:lang=""><![CDATA[Multiple sclerosis risk after optic neuritis: final optic neuritis treatment trial follow-up]]></article-title>
<source><![CDATA[Arch Neurol]]></source>
<year>2008</year>
<volume>65</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>727-32</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kuhle]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Disanto]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Dobson]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Adiutori]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Bianchi]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Topping]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study]]></article-title>
<source><![CDATA[Mult Scler J]]></source>
<year>2015</year>
<volume>21</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1013-24</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tintore]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Rovira]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Arrambide]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Mitjana]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Río]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Auger]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Brainstem lesions in clinically isolated syndromes]]></article-title>
<source><![CDATA[Neurology]]></source>
<year>2010</year>
<volume>75</volume>
<numero>21</numero>
<issue>21</issue>
<page-range>1933-8</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Odenthal]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Coulthard]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The prognostic utility of MRI in clinically isolated syndrome: A literature review]]></article-title>
<source><![CDATA[Am J Neuroradiol]]></source>
<year>2014</year>
<volume>36</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>425-31</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bakshi]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Minagar]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Jaisani]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Wolinsky]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Imaging of multiple sclerosis: role in neurotherapeutics]]></article-title>
<source><![CDATA[NeuroRx]]></source>
<year>2005</year>
<volume>2</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>277-303</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cordonnier]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[de Seze]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Breteau]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Ferriby]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Michelin]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Stojkovic]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prospective study of patients presenting with acute partial transverse myelopathy]]></article-title>
<source><![CDATA[J Neurol]]></source>
<year>2003</year>
<volume>250</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1447-52</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Thompson]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Banwell]]></surname>
<given-names><![CDATA[BL]]></given-names>
</name>
<name>
<surname><![CDATA[Barkhof]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Carroll]]></surname>
<given-names><![CDATA[WM]]></given-names>
</name>
<name>
<surname><![CDATA[Coetzee]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Comi]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria]]></article-title>
<source><![CDATA[Lancet Neurol]]></source>
<year>2017</year>
<volume>17</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>162-73</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Calabrese]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Rinaldi]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Mattisi]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Bernardi]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Favaretto]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Perini]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The predictive value of gray matter atrophy in clinically isolated syndromes]]></article-title>
<source><![CDATA[Neurology]]></source>
<year>2011</year>
<volume>77</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>257-63</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Traboulsee]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Simon]]></surname>
<given-names><![CDATA[JH]]></given-names>
</name>
<name>
<surname><![CDATA[Stone]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Fisher]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Jones]]></surname>
<given-names><![CDATA[DE]]></given-names>
</name>
<name>
<surname><![CDATA[Mal-hotra]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Revised recommendations of the consortium of MS centers task force for a standardized MRI protocol and clinical guidelines for the diagnosis and follow-up of multiple sclerosis]]></article-title>
<source><![CDATA[Am J Neuroradiol]]></source>
<year>2016</year>
<volume>37</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>394-401</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Filippi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Rocca]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Ciccarelli]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[De Stefano]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Evangelou]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Kappos]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines]]></article-title>
<source><![CDATA[Lancet Neurol]]></source>
<year>2016</year>
<volume>15</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>292-303</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wagner]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Williams]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Webster]]></surname>
<given-names><![CDATA[CJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Biomarkers and surrogate end points for fit-for-purpose development and regulatory evaluation of new drugs]]></article-title>
<source><![CDATA[Clin Pharmacol Ther]]></source>
<year>2007</year>
<volume>81</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>104-7</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fitzner]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Hecker]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Zettl]]></surname>
<given-names><![CDATA[UK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Molecular biomarkers in cerebrospinal fluid of multiple sclerosis patients]]></article-title>
<source><![CDATA[Autoimmun Rev]]></source>
<year>2015</year>
<volume>14</volume>
<page-range>903-13</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Freedman]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Thompson]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
<name>
<surname><![CDATA[Deisenhammer]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Giovannoni]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Grimsley]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Keir]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: a consensus statement]]></article-title>
<source><![CDATA[Arch Neurol]]></source>
<year>2005</year>
<volume>62</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>865-70</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Masjuan]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Alvarez-Cermeño]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[García-Barragán]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Díaz-Sánchez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Espiño]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Sádaba]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinically isolated syndromes: A new oligoclonal band test accurately predicts conversion to MS]]></article-title>
<source><![CDATA[Neurology]]></source>
<year>2006</year>
<volume>66</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>576-8</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tintoré]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Rovira]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Río]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Tur]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Pelayo]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Nos]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis?]]></article-title>
<source><![CDATA[Neurology]]></source>
<year>2008</year>
<volume>70</volume>
<numero>13^s2</numero>
<issue>13^s2</issue>
<supplement>2</supplement>
<page-range>1079-83</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Comabella]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Fernández]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Martin]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Rivera-Vallvé]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Borrás]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Chiva]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis]]></article-title>
<source><![CDATA[Brain]]></source>
<year>2010</year>
<volume>133</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>1082-93</page-range></nlm-citation>
</ref>
<ref id="B33">
<label>33</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Teunissen]]></surname>
<given-names><![CDATA[CE]]></given-names>
</name>
<name>
<surname><![CDATA[Iacobaeus]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Khademi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Brundin]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Norgren]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Koel-Simmelink]]></surname>
<given-names><![CDATA[MJA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis]]></article-title>
<source><![CDATA[Neurology]]></source>
<year>2009</year>
<volume>72</volume>
<numero>15</numero>
<issue>15</issue>
<page-range>1322-9</page-range></nlm-citation>
</ref>
<ref id="B34">
<label>34</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Norgren]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Sundstrom]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Svenningsson]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Rosengren]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Stigbrand]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Gunnarsson]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Neurofilament and glial fibrillary acidic protein in multiple sclerosis]]></article-title>
<source><![CDATA[Neurology]]></source>
<year>2004</year>
<volume>63</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>1586-90</page-range></nlm-citation>
</ref>
<ref id="B35">
<label>35</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mowry]]></surname>
<given-names><![CDATA[EM]]></given-names>
</name>
<name>
<surname><![CDATA[Pesic]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Grimes]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Deen]]></surname>
<given-names><![CDATA[SR]]></given-names>
</name>
<name>
<surname><![CDATA[Bacchetti]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Waubant]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical predictors of early second event in patients with clinically isolated syndrome]]></article-title>
<source><![CDATA[J Neurol]]></source>
<year>2009</year>
<volume>256</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>1061-6</page-range></nlm-citation>
</ref>
<ref id="B36">
<label>36</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dobson]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Ramagopalan]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Giovannoni]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The effect of gender in clinically isolated syndrome (CIS): a meta-analysis]]></article-title>
<source><![CDATA[Mult Scler]]></source>
<year>2012</year>
<volume>18</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>600-4</page-range></nlm-citation>
</ref>
<ref id="B37">
<label>37</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Polman]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Kappos]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Freedman]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Edan]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Hartung]]></surname>
<given-names><![CDATA[HP]]></given-names>
</name>
<name>
<surname><![CDATA[Miller]]></surname>
<given-names><![CDATA[DH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Subgroups of the BENEFIT study: Risk of developing MS and treatment effect of interferon beta-1b]]></article-title>
<source><![CDATA[J Neurol]]></source>
<year>2008</year>
<volume>255</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>480-7</page-range></nlm-citation>
</ref>
<ref id="B38">
<label>38</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jacobs]]></surname>
<given-names><![CDATA[LD]]></given-names>
</name>
<name>
<surname><![CDATA[Beck]]></surname>
<given-names><![CDATA[RW]]></given-names>
</name>
<name>
<surname><![CDATA[Simon]]></surname>
<given-names><![CDATA[JH]]></given-names>
</name>
<name>
<surname><![CDATA[Kinkel]]></surname>
<given-names><![CDATA[RP]]></given-names>
</name>
<name>
<surname><![CDATA[Brownscheidle]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[Murray]]></surname>
<given-names><![CDATA[TJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2000</year>
<volume>343</volume>
<numero>13</numero>
<issue>13</issue>
<page-range>898-904</page-range></nlm-citation>
</ref>
<ref id="B39">
<label>39</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dobson]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Giovannoni]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Ramagopalan]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The month of birth effect in multiple sclerosis: systematic review, meta-analysis and effect of latitude]]></article-title>
<source><![CDATA[J Neurol Neurosurg Psychiatry]]></source>
<year>2012</year>
<volume>84</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>472-83</page-range></nlm-citation>
</ref>
<ref id="B40">
<label>40</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wing]]></surname>
<given-names><![CDATA[AC]]></given-names>
</name>
<name>
<surname><![CDATA[Vasconcelos]]></surname>
<given-names><![CDATA[CCF]]></given-names>
</name>
<name>
<surname><![CDATA[Calvet]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Papais-Alvarenga]]></surname>
<given-names><![CDATA[RM]]></given-names>
</name>
<name>
<surname><![CDATA[Thuler]]></surname>
<given-names><![CDATA[LCS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Risk factors for convertion to clinically defined multiple sclerosis after clinically isolated syndrome in a racially mixed Brazilian cohort]]></article-title>
<source><![CDATA[Clin Neurol Neurosurg]]></source>
<year>2016</year>
<volume>146</volume>
<page-range>40-4</page-range></nlm-citation>
</ref>
<ref id="B41">
<label>41</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sand]]></surname>
<given-names><![CDATA[IK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Classification, diagnosis, and differential diagnosis of multiple sclerosis]]></article-title>
<source><![CDATA[Curr Opin Neurol]]></source>
<year>2015</year>
<volume>28</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>193-205</page-range></nlm-citation>
</ref>
<ref id="B42">
<label>42</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shimizu]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Hatanaka]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Hasegawa]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Iwata]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Sugimoto]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Date]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[IFN??-1b may severely exacerbate Japanese optic-spinal MS in neuromyelitis optica spectrum]]></article-title>
<source><![CDATA[Neurology]]></source>
<year>2010</year>
<volume>75</volume>
<numero>16</numero>
<issue>16</issue>
<page-range>1423-7</page-range></nlm-citation>
</ref>
<ref id="B43">
<label>43</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wingerchuk]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
<name>
<surname><![CDATA[Lennon]]></surname>
<given-names><![CDATA[VA]]></given-names>
</name>
<name>
<surname><![CDATA[Lucchinetti]]></surname>
<given-names><![CDATA[CF]]></given-names>
</name>
<name>
<surname><![CDATA[Pittock]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[Weinshenker]]></surname>
<given-names><![CDATA[BG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The spectrum of neuromyelitis optica]]></article-title>
<source><![CDATA[Lancet Neurol]]></source>
<year>2007</year>
<volume>6</volume>
<page-range>805-15</page-range></nlm-citation>
</ref>
<ref id="B44">
<label>44</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wingerchuk]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
<name>
<surname><![CDATA[Weinshenker]]></surname>
<given-names><![CDATA[BG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Neuromyelitis optica: clinical predictors of a relapsing course and survival]]></article-title>
<source><![CDATA[Neurology]]></source>
<year>2003</year>
<volume>60</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>848-53</page-range></nlm-citation>
</ref>
<ref id="B45">
<label>45</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jarius]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Paul]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Franciotta]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Ruprecht]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Ringelstein]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Bergamaschi]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cerebrospinal fluid findings in aqua-porin-4 antibody positive neuromyelitis optica: results from 211 lumbar punctures]]></article-title>
<source><![CDATA[J Neurol Sci]]></source>
<year>2011</year>
<volume>306</volume>
<numero>1-2</numero>
<issue>1-2</issue>
<page-range>82-90</page-range></nlm-citation>
</ref>
<ref id="B46">
<label>46</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hyun]]></surname>
<given-names><![CDATA[JW]]></given-names>
</name>
<name>
<surname><![CDATA[Jeong]]></surname>
<given-names><![CDATA[IH]]></given-names>
</name>
<name>
<surname><![CDATA[Joung]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[S-H]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[HJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evaluation of the 2015 diagnostic criteria for neuromyelitis optica spectrum disorder]]></article-title>
<source><![CDATA[Neurology]]></source>
<year>2016</year>
<volume>86</volume>
<numero>19</numero>
<issue>19</issue>
<page-range>1772-9</page-range></nlm-citation>
</ref>
<ref id="B47">
<label>47</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wingerchuk]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
<name>
<surname><![CDATA[Banwell]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Bennett]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Cabre]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Carroll W Chitnis]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[International consensus diagnostic criteria for neuromyelitis optica spectrum disorders]]></article-title>
<source><![CDATA[Neurology]]></source>
<year>2015</year>
<volume>85</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>177-89</page-range></nlm-citation>
</ref>
<ref id="B48">
<label>48</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tenembaum]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Chamoles]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Fejerman]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Acute disseminated encephalomyelitis: a long-term follow-up study of 84 pediatric patients]]></article-title>
<source><![CDATA[Neurology]]></source>
<year>2002</year>
<volume>59</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1224-31</page-range></nlm-citation>
</ref>
<ref id="B49">
<label>49</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pohl]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Alper]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Van Haren]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Kornberg]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Lucchinetti]]></surname>
<given-names><![CDATA[CF]]></given-names>
</name>
<name>
<surname><![CDATA[Tenembaum]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Acute disseminated encephalomyelitis: Updates on an inflammatory CNS syndrome]]></article-title>
<source><![CDATA[Neurology]]></source>
<year>2016</year>
<volume>87</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>S38-45</page-range></nlm-citation>
</ref>
<ref id="B50">
<label>50</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kamate]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Chetal]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Tonape]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Mahantshetti]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Hattiholi]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Central nervous system inflammatory demyelinating disorders of childhood]]></article-title>
<source><![CDATA[Ann Indian Acad Neurol]]></source>
<year>2010</year>
<volume>13</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>289-92</page-range></nlm-citation>
</ref>
<ref id="B51">
<label>51</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Comi]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Filippi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Barkhof]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Durelli]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Edan]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Fernández]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of early interferon treatment on conversion to definite multiple sclerosis: A randomised study]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2001</year>
<volume>357</volume>
<numero>9268</numero>
<issue>9268</issue>
<page-range>1576-82</page-range></nlm-citation>
</ref>
<ref id="B52">
<label>52</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Beck]]></surname>
<given-names><![CDATA[RW]]></given-names>
</name>
<name>
<surname><![CDATA[Cleary]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Optic neuritis treatment trial. One-year follow-up results]]></article-title>
<source><![CDATA[Arch Ophthalmol]]></source>
<year>1993</year>
<volume>111</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>773-5</page-range></nlm-citation>
</ref>
<ref id="B53">
<label>53</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dovio]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Perazzolo]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Osella]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Ventura]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Termine]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Milano]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Immediate fall of bone formation and transient increase of bone resorption in the course of high-dose, short-term glucocorticoid therapy in young patients with multiple sclerosis]]></article-title>
<source><![CDATA[J Clin Endocrinol Metab]]></source>
<year>2004</year>
<volume>89</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>4923-8</page-range></nlm-citation>
</ref>
<ref id="B54">
<label>54</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lyons]]></surname>
<given-names><![CDATA[PR]]></given-names>
</name>
<name>
<surname><![CDATA[Newman]]></surname>
<given-names><![CDATA[PK]]></given-names>
</name>
<name>
<surname><![CDATA[Saunders]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Methylprednisolone therapy in multiple sclerosis: a profile of adverse effects]]></article-title>
<source><![CDATA[J Neurol Neurosurg Psychiatry]]></source>
<year>1988</year>
<volume>51</volume>
<page-range>285-7</page-range></nlm-citation>
</ref>
<ref id="B55">
<label>55</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tintore]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Rovira]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Río]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Otero-Romero]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Arrambide]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Tur]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Defining high, medium and low impact prognostic factors for developing multiple sclerosis]]></article-title>
<source><![CDATA[Brain]]></source>
<year>2015</year>
<volume>138</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>1863-74</page-range></nlm-citation>
</ref>
<ref id="B56">
<label>56</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kappos]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Polman]]></surname>
<given-names><![CDATA[CH]]></given-names>
</name>
<name>
<surname><![CDATA[Freedman]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Edan]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Hartung]]></surname>
<given-names><![CDATA[HP]]></given-names>
</name>
<name>
<surname><![CDATA[Miller]]></surname>
<given-names><![CDATA[DH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes]]></article-title>
<source><![CDATA[Neurology]]></source>
<year>2006</year>
<volume>67</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>1242-9</page-range></nlm-citation>
</ref>
<ref id="B57">
<label>57</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Comi]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Martinelli]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Rodegher]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Moiola]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Bajenaru]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Carra]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial]]></article-title>
<source><![CDATA[The Lancet]]></source>
<year>2009</year>
<volume>374</volume>
<numero>9700</numero>
<issue>9700</issue>
<page-range>1503-11</page-range></nlm-citation>
</ref>
<ref id="B58">
<label>58</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kinkel]]></surname>
<given-names><![CDATA[RP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event]]></article-title>
<source><![CDATA[Neurology]]></source>
<year>2006</year>
<volume>66</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>678-84</page-range></nlm-citation>
</ref>
<ref id="B59">
<label>59</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Miller]]></surname>
<given-names><![CDATA[AE]]></given-names>
</name>
<name>
<surname><![CDATA[Wolinsky]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
<name>
<surname><![CDATA[Kappos]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Comi]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Freedman]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Olsson]]></surname>
<given-names><![CDATA[TP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): A randomised, doubleblind, placebo-controlled, phase 3 trial]]></article-title>
<source><![CDATA[Lancet Neurol]]></source>
<year>2014</year>
<volume>13</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>977-86</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
